PharmaShots | Incisive News in 3 Shots

Subscribe Now

dizal

Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer

Dizal Reports the Regulatory Submission of Sunvozertinib to the US FDA for Treating R/R Non-Small Cell Lung Cancer

November 8, 2024

Dizal’s Sunvozertinib Receives the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of NSCLC with EGFR Mutations

Dizal’s Sunvozertinib Receives the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of NSCLC with EGFR Mutations

October 15, 2024

Dizal’s Golidocitinib Gains the NMPA’s Approval to Treat Peripheral T-Cell Lymphoma

Dizal’s Golidocitinib Gains the NMPA’s Approval to Treat Peripheral T-Cell Lymphoma

June 20, 2024

Dizal's Sunvozertinib Receives the NMPA’s Approval for Non-Small Cell Lung Cancer with EGFR Exon20ins Mutations

Dizal's Sunvozertinib Receives the NMPA’s Approval for Non-Small Cell Lung Cancer with EGFR Exon20ins Mutations

August 24, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us